Development of non-invasive treatment for Parkinson's disease with violet light

Genko Oyama0 sites20 target enrollmentSeptember 1, 2020

Overview

No summary available.

Registry

who.int

Start Date

September 1, 2020

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Genko Oyama

•1\)Patients diagnosed with Parkinson's disease according to MDS clinical diagnostic criteria for Parkinson's disease
•2\)Patients who have not changed or added any of the settings of levodopa preparation, dopamine agonist, antiparkinsonism drug, deep brain stimulator (DBS) within 4 weeks before obtaining consent
•3\)Patients with Modified Hoehn \& Yahr severity of 4 degrees or less (4 degrees or less when off if there is a wear\-off)
•4\)Patients with visual hallucinations (noise parade rear test 1 point or more)
•5\)It does not matter whether the patient is hospitalized or outpatient (outpatient preferred)
•6\)Patients who can assist wearing violet light irradiation goggles
•7\)Patients who can spend 3 hours in the daytime (11:00 to 14:00 as a guide) with the naked eyes when wearing violet light irradiation goggles
•8\)Men and women over the age of 20
•9\)Patients with written informed consent to participate in this study

•1\)Patients on continuous levodopa\-carbidopa intestinal gel (LCIG) within 4 weeks before obtaining consent
•2\)Patients with epilepsy, severe heart, lung, kidney, liver or digestive disorders
•3\)Patients with severe cataract (nuclear sclerosis grade 3 or more)
•4\)Patient who performed ophthalmic surgery within 6 months before obtaining consent
•5\)Patients with retinal abnormalities such as serous retinal detachment and retinal hemorrhage
•6\)Patients with a history of seizures or epilepsy
•7\)Patients with a history of cancer or patients with serious diseases such as cancer
•8\)Patients who are pregnant or breastfeeding
•9\)Other patients who are judged to be unsuitable by the investigator